|Bid||31.88 x 800|
|Ask||33.47 x 800|
|Day's Range||31.80 - 32.47|
|52 Week Range||22.00 - 36.00|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||40.50|
The direct benefit for Principia Biopharma Inc. (NASDAQ:PRNB), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. However, the trade-off Read More...
Principia Biopharma Inc. (PRNB), a clinical-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology today issued the following statement: “It is with great sadness that we announce that Lewis (Lew) J. Shuster, a member of the company’s board of directors, died last week due to recently diagnosed, late-stage pancreatic cancer. The entire Principia team mourns the loss of Lew and he will be dearly missed. Lew was a tremendously thoughtful and insightful board member, but more importantly, he was a kind and generous individual who brought a great deal of passion and energy to our industry and to the pursuit of our mission.
Gilead's CEO search, Amyris' cannabis consideration and Principia's opportunity in this week's Health Care Digest.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 29) Allakos Inc (NASDAQ: ALLK ) Emergent Biosolutions Inc ...
NEW YORK, Nov. 15, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Principia Biopharma Inc. (PRNB), a clinical-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology, today announced that management will present at the 27th Annual Credit Suisse Healthcare Conference on Thursday, November 15, 2018, at 8:35 a.m. MT (10:35 a.m. ET) at the Phoenician in Scottsdale, Arizona. The presentation will be available via live webcast from the “Events and Presentations” page of the “Investors” section of the Company’s website. Principia Biopharma is a clinical-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology.
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2018 -- Principia Biopharma Inc. (Nasdaq: PRNB), a clinical-stage biopharmaceutical company dedicated to bringing transformative oral.
- Succession designed to lead Principia through next phase of growth as a clinical-stage company - SOUTH SAN FRANCISCO, Calif., Oct. 24, 2018 -- Principia Biopharma Inc..
Biotech companies must do more to train, mentor and guide millennials, including pairing them with older colleagues, according to members of a recent panel.
NEW YORK, NY / ACCESSWIRE / September 17, 2018 / Biotech stocks Unity Biotechnology and Principia Biopharma had exciting trading days on Friday. Shares of Unity saw more gains on Friday after exploding last Thursday when its CEO spoke on CNBC’s “Power Lunch” about the company’s plans. Amazon CEO Jeff Bezos is an investor in the company.